Press Release
Arcadia Biosciences Announces Second-Quarter and First-Half 2020 Financial Results and Business Highlights
"Amidst an incredibly challenging economic landscape, I am pleased to report Arcadia has achieved a number of key milestones across each of the crop product areas in which we innovate: hemp, wheat and soy," said
"Furthermore, against the buffeting of COVID-19 headwinds, we strengthened our cash position by
Recent Operating and Business Highlights
- Collaboration with
Corner Foods to Bring GoodWheat toChina andIsrael . Arcadia's collaboration withCorner Foods , an affiliate ofCorner Capital Group , brings Arcadia's GoodWheat portfolio of non-GMO specialty wheat ingredients toChina andIsrael . The partnership will introduce GoodWheat products directly to consumers inChina via popular e-commerce site TMall and cooking and lifestyle network Tastemade China. Together, these digital platforms reach an estimated eight million consumers inChina per month. Arcadia andCorner Foods also plan for introductions into food retail and food service markets inIsrael , long known for food tech innovation focused on healthful ingredients. - Partnership with Three Farm Daughters to Develop and Market GoodWheat Products. This week Arcadia announced the execution of a term sheet to form a strategic business venture with Three Farm Daughters, a majority female-owned
North Dakota -based consumer food company, to develop and market food products using Arcadia's patented non-GMO GoodWheat technology. Together, the companies will develop Three Farm Daughters-branded food products such as flours, pastas and crackers that leverage the enhanced nutritional profiles of GoodWheat ingredients. Three Farm Daughters products will be sold in grocery stores, on Amazon and through the company's e-commerce site: www.threefarmdaughters.com. - Collaboration with
GoodMills to Sell GoodWheat inEurope . Through a collaboration with GoodMills Innovation, an affiliate ofGoodMills Group ,Europe's largest milling company, Arcadia plans to commercialize GoodWheat varieties acrossEurope , introducing uniquely healthy products for the retail, consumer and food service sectors beginning in 2020. GoodMills Innovation is recognized as one of the world's leading innovators in grain-based ingredients that are both highly functional and nutritional. - Acquisition of
Innovative Hemp Seed Breeding Company . Arcadia is closing a transaction with Industrial Seed Innovations (ISI), anOregon -based industrial hemp breeding and seed company, to acquire its commercial and genetic assets, including seed varieties, germplasm library and intellectual property. ISI's popular Rogue andUmpqua seed varieties will become part of Arcadia's portfolio, alongside the company's GoodHemp line of genetically superior hemp seeds, transplants, flowers and extracts. The acquisition will significantly broaden and accelerate commercialization of Arcadia's hemp-related breeding platform and establish a breeding research and development facility in thePacific Northwest , a key hemp production area. - Global Scale-up Underway for HB4 Drought Resistant, Herbicide Tolerant Soybeans. Through its Verdeca joint venture with Bioceres Crop Solutions, Arcadia successfully harvested foundation seed to enable up to 90,000 hectares in preparation for regulatory approval from
China . Verdeca is also increasing breeding and new market development activities to access incremental geographies, includingBrazil and theU.S. - Inclusion in Russell Microcap Index. At the end of June, Arcadia joined the Russell Microcap®Index (^RUMIC). Membership in the Index, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes, which are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Arcadia's inclusion in the Russell Microcap Index will increase investor awareness and broaden its investor base at a time when the company is focused on scaling revenues through the sales of GoodHemp and GoodWheat seed and grain, as well as the introduction of its Hawaiian CBD products in 2020.
- Expansion of Intellectual Property Protection for GoodWheat Portfolio. Arcadia strengthened its intellectual property and GoodWheat technology portfolio with five additional
U.S. patents in Q2. TheU.S. Patent and Trademark Office awarded the company two patents for extending the shelf life of whole wheat by minimizing hydrolytic and oxidative rancidity. The company also received notices of allowance for three additional patents extending earlier claims surrounding the extended shelf life of wheat and reduced gluten grains. The new patents bring the total number of patents in Arcadia's GoodWheat portfolio of non-GMO wheat varieties to 23. - Foundational Patents for Non-GMO Herbicide Tolerant Wheat. The Australian Patent Office granted patents to Arcadia covering herbicide tolerance in wheat, and the
U.S. Patent and Trademark Office issued a notice of allowance for the same technology, with patents pending in other territories. Arcadia's herbicide tolerant wheat technology can be an important tool in the hybrid breeding toolkit. This technology will serve as the foundation for future innovation and could open the door to development of a highly efficient hybrid wheat production system, which would transform the 200 million hectare global wheat industry. Randy Shultz , Ph.D. Named Chief Technology Officer. Early in Q2, Arcadia promotedRandy Shultz , Ph.D. to the role of chief technology officer. Shultz joined Arcadia in 2019 as head of research and development and has played an instrumental role in accelerating novel non-GMO hemp varieties with ArcaTechTM, Arcadia's proprietary rapid prototyping and development platform. In this new, elevated position, Shultz oversees the execution of Arcadia's strategic, multi-year plan to become a market leader in high-value hemp innovations, as well as continuing to advance next generation products through the company's GoodWheat pipeline.- Warrant Exercise Transactions Exceed
$9 Million . Arcadia strengthened its balance sheet through two separate warrant exercise transactions in Q2 and Q3, providing additional cash resources to persevere through the headwinds of the COVID-19 pandemic. Proceeds from the transactions with current investors will enable the company to advance its growth strategy, fund product commercialization activities and transform its business through the potential acquisition of assets adding value and speed to its hemp products business.
|
|||||||||
Financial Snapshot |
|||||||||
(Unaudited) |
|||||||||
($ in thousands) |
|||||||||
Three Months Ended |
Six Months Ended |
||||||||
2020 |
2019 |
Favorable/ |
2020 |
2019 |
Favorable/ |
||||
$ |
% |
$ |
% |
||||||
Total Revenues |
281 |
203 |
78 |
38% |
590 |
361 |
229 |
63% |
|
Total Operating Expenses |
7,157 |
5,185 |
(1,972) |
(38)% |
13,256 |
9,561 |
(3,695) |
(39)% |
|
Loss From Operations |
(6,876) |
(4,982) |
(1,894) |
(38)% |
(12,666) |
(9,200) |
(3,466) |
(38)% |
|
Net Income (Loss) attributable to common stockholders |
(9,689) |
4,237 |
(13,926) |
(329)% |
(7,164) |
(8,375) |
1,211 |
14% |
Revenues
In the second quarter of 2020, revenues were
Operating Expenses
In the second quarter of 2020, operating expenses were
Net Income Attributable to Common Stockholders
Net loss attributable to common shareholders for the second quarter of 2020 was
Net loss attributable to common shareholders for the first half of 2020 was
Conference Call and Webcast
The company has scheduled a conference call for
Interested participants can join the conference call using the following numbers:
|
+1-844-243-4690 |
International Dial-In: |
+1-225-283-0138 |
Passcode: |
9398996 |
A live webcast of the conference call will be available on the "Investors" section of Arcadia's website at www.arcadiabio.com. Following completion of the call, a recorded replay will be available on the company's investor website.
About
Safe Harbor Statement
"Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995: This press release and the accompanying conference call contain forward-looking statements about the company and its products, including statements relating to the collaboration with
LinkedIn:
Twitter: @ArcadiaAg
|
|||
Condensed Consolidated Balance Sheets |
|||
(Unaudited) |
|||
(In thousands, except share data) |
|||
|
|
||
Assets |
|||
Current assets: |
|||
Cash and cash equivalents |
$ 14,995 |
$ 8,417 |
|
Short-term investments |
600 |
16,915 |
|
Accounts receivable |
403 |
602 |
|
Inventories, net — current |
8,772 |
1,794 |
|
Prepaid expenses and other current assets |
1,326 |
712 |
|
Total current assets |
26,096 |
28,440 |
|
Restricted cash |
2,000 |
— |
|
Property and equipment, net |
3,403 |
1,799 |
|
Right of use asset |
5,598 |
1,963 |
|
Inventories, net — noncurrent |
658 |
364 |
|
Other noncurrent assets |
23 |
8 |
|
Total assets |
$ 37,778 |
$ 32,574 |
|
Liabilities and stockholders' equity |
|||
Current liabilities: |
|||
Accounts payable and accrued expenses |
$ 6,937 |
$ 4,685 |
|
Amounts due to related parties |
22 |
40 |
|
Debt — current |
519 |
24 |
|
Unearned revenue — current |
— |
42 |
|
Operating lease liability — current |
623 |
611 |
|
Other current liabilities |
263 |
306 |
|
Total current liabilities |
8,364 |
5,708 |
|
Debt — noncurrent |
2,742 |
107 |
|
Operating lease liability — noncurrent |
5,220 |
1,497 |
|
Common stock warrant liabilities |
5,836 |
14,936 |
|
Other noncurrent liabilities |
2,000 |
2,000 |
|
Total liabilities |
24,162 |
24,248 |
|
Stockholders' equity: |
|||
Common stock, |
50 |
49 |
|
Additional paid-in capital |
226,405 |
214,826 |
|
Accumulated other comprehensive income |
— |
1 |
|
Accumulated deficit |
(214,335) |
(207,171) |
|
Total |
12,120 |
7,705 |
|
Non-controlling interest |
1,496 |
621 |
|
Total stockholders' equity |
13,616 |
8,326 |
|
Total liabilities and stockholders' equity |
$ 37,778 |
$ 32,574 |
|
||||||||
Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income |
||||||||
(Unaudited) |
||||||||
(In thousands, except share and per share data) |
||||||||
Three Months Ended |
Six Months Ended |
|||||||
2020 |
2019 |
2020 |
2019 |
|||||
Revenues: |
||||||||
Product |
$ 231 |
$ 162 |
$ 385 |
$ 269 |
||||
License |
— |
— |
100 |
— |
||||
Royalty |
12 |
— |
42 |
— |
||||
Contract research and government grants |
38 |
41 |
63 |
92 |
||||
Total revenues |
281 |
203 |
590 |
361 |
||||
Operating expenses: |
||||||||
Cost of product revenues |
1,490 |
89 |
1,622 |
148 |
||||
Research and development |
1,993 |
1,950 |
4,237 |
3,456 |
||||
Selling, general and administrative |
3,674 |
3,146 |
7,397 |
5,957 |
||||
Total operating expenses |
7,157 |
5,185 |
13,256 |
9,561 |
||||
Loss from operations |
(6,876) |
(4,982) |
(12,666) |
(9,200) |
||||
Interest expense |
(6) |
— |
(9) |
— |
||||
Other income, net |
10 |
101 |
82 |
221 |
||||
Change in fair value of common stock warrant liabilities |
(3,079) |
9,482 |
5,082 |
987 |
||||
Gain on extinguishment of warrant liability |
47 |
— |
47 |
— |
||||
Offering costs |
— |
(365) |
— |
(365) |
||||
Net (loss) income before income taxes |
(9,904) |
4,236 |
(7,464) |
(8,357) |
||||
Income tax benefit (provision) |
10 |
1 |
(7) |
(18) |
||||
Net (loss) income |
(9,894) |
4,237 |
(7,471) |
(8,375) |
||||
Net loss attributable to non-controlling interest |
(205) |
— |
(307) |
— |
||||
Net (loss) income attributable to common stockholders |
$ (9,689) |
$ 4,237 |
$ (7,164) |
$ (8,375) |
||||
Net (loss) income per share attributable to common stockholders: |
||||||||
Basic and diluted |
(1.04) |
0.84 |
(0.80) |
(1.70) |
||||
Weighted-average number of shares used in per share calculations: |
||||||||
Basic and diluted |
9,327,317 |
5,054,812 |
8,989,265 |
4,916,116 |
||||
Other comprehensive loss, net of tax |
||||||||
Unrealized losses on available-for-sale securities |
— |
— |
(1) |
— |
||||
Other comprehensive loss |
— |
— |
(1) |
— |
||||
Comprehensive (loss) income attributable to common stockholders |
$ (9,689) |
$ 4,237 |
$ (7,165) |
$ (8,375) |
|
|||
Condensed Consolidated Statements of Cash Flows |
|||
(Unaudited) |
|||
(In thousands) |
|||
Six Months Ended |
|||
2020 |
2019 |
||
CASH FLOWS FROM OPERATING ACTIVITIES: |
|||
Net loss |
$ (7,471) |
$ (8,375) |
|
Adjustments to reconcile net loss to cash used in operating activities: |
|||
Change in fair value of common stock warrant liabilities |
(5,082) |
(987) |
|
Gain on extinguishment of warrant liability |
(47) |
— |
|
Offering costs |
— |
365 |
|
Depreciation |
182 |
77 |
|
Lease amortization |
484 |
348 |
|
Net amortization of investment premium |
(44) |
(82) |
|
Stock-based compensation |
1,367 |
811 |
|
Write-down of inventory and prepaid production costs |
1,421 |
— |
|
Changes in operating assets and liabilities: |
|||
Accounts receivable |
199 |
40 |
|
Inventories |
(8,031) |
(561) |
|
Prepaid expenses and other current assets |
(1,276) |
(302) |
|
Other noncurrent assets |
(15) |
— |
|
Accounts payable and accrued expenses |
2,252 |
677 |
|
Amounts due to related parties |
(18) |
(10) |
|
Other noncurrent liabilities |
(43) |
— |
|
Unearned revenue |
(42) |
(81) |
|
Operating lease payments |
(384) |
(349) |
|
Net cash used in operating activities |
(16,548) |
(8,429) |
|
CASH FLOWS FROM INVESTING ACTIVITIES: |
|||
Purchases of property and equipment |
(1,749) |
(315) |
|
Purchases of investments |
(1,292) |
(8,623) |
|
Proceeds from sales and maturities of investments |
17,650 |
13,150 |
|
Net cash provided by investing activities |
14,609 |
4,212 |
|
CASH FLOWS FROM FINANCING ACTIVITIES: |
|||
Proceeds from warrant exercises from |
6,822 |
— |
|
Proceeds from borrowings |
3,108 |
— |
|
Payments of transaction costs relating to extinguishment of warrant liability |
(594) |
— |
|
Proceeds from issuance of common stock and warrants from |
— |
7,500 |
|
Payments of offering costs relating to |
— |
(619) |
|
Payments of offering costs relating to |
— |
(24) |
|
Principal payments on notes payable |
(15) |
— |
|
Proceeds from ESPP purchases |
14 |
8 |
|
Capital contributions received from non-controlling interest |
1,182 |
— |
|
Net cash provided by financing activities |
10,517 |
6,865 |
|
Net increase in cash, cash equivalents and restricted cash |
8,578 |
2,648 |
|
Cash, cash equivalents and restricted cash — beginning of period |
8,417 |
11,998 |
|
Cash, cash equivalents and restricted cash — end of period |
$ 16,995 |
$ 14,646 |
|
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION: |
|||
Cash paid for income taxes |
$ — |
$ 2 |
|
Cash paid for interest |
$ 6 |
$ — |
|
NONCASH INVESTING AND FINANCING ACTIVITIES: |
|||
Fixed assets acquired with notes payable |
$ 37 |
$ — |
|
Common stock warrants issued to placement agent and included in offering costs related to |
$ 215 |
$ — |
|
Offering costs in accounts payable and accrued expenses at end of period |
$ — |
$ 22 |
|
Common stock warrants issued to placement agent and included in offering costs related to |
$ — |
$ 86 |
|
Right of use assets obtained in exchange for new operating lease liabilities |
$ 3,947 |
$ 2,328 |
|
Purchases of fixed assets included in accounts payable and accrued expenses |
$ — |
$ 6 |
View original content to download multimedia:http://www.prnewswire.com/news-releases/arcadia-biosciences-announces-second-quarter-and-first-half-2020-financial-results-and-business-highlights-301112160.html
SOURCE
Press, Lisa Weser, Trailblaze, lisa@trailblaze.co; Investors, Pam Haley, Chief Financial Officer, ir@arcadiabio.com